salvage therapy

Ask MedXY AI

Latest news

Tag

$Enhanced Salvage Therapy in Relapsed/Refractory AML: Venetoclax Plus High-Dose Cytarabine and Mitoxantrone Shows Promising Outcomes and Risk Stratification Insights$

Hematology-Oncologyhematopoietic cell transplantationacute myeloid leukemia

Enhanced Salvage Therapy in Relapsed/Refractory AML: Venetoclax Plus High-Dose Cytarabine and Mitoxantrone Shows Promising Outcomes and Risk Stratification Insights

By MedXY|Aug 24, 2026

A multicenter real-world study demonstrates that combining venetoclax with high-dose cytarabine and mitoxantrone significantly improves remission and survival rates in relapsed/refractory AML, with validated risk factors guiding prognostica

Diabetes & Endocrinologythyroid cancerPemetrexed

Evaluating Pemetrexed Monotherapy and Combination Therapy with Carboplatin in Advanced Thyroid Cancer: A Retrospective Cohort Analysis

By MedXY|Aug 4, 2026

This retrospective study assesses the efficacy and safety of pemetrexed, alone or combined with carboplatin, as salvage therapy for advanced thyroid cancer, showing promising response rates comparable to current second-line treatments.

newsFocal Therapyprostate cancer

Salvage Focal Therapy vs. Radical Prostatectomy: Comparable 10-Year Survival with Dramatically Reduced Morbidity

By MedXY|Feb 20, 2026

A landmark multicenter study indicates that salvage focal therapy (sFT) achieves long-term cancer-specific survival comparable to salvage radical prostatectomy (sRP) while significantly lowering the risk of major perioperative complications

$Venetoclax plus Azacitidine Emerges as a Potent Salvage Therapy for Relapsed or Refractory T-cell Acute Lymphoblastic Leukaemia$

Hematology-Oncologysalvage therapyvenetoclax

Venetoclax plus Azacitidine Emerges as a Potent Salvage Therapy for Relapsed or Refractory T-cell Acute Lymphoblastic Leukaemia

By MedXY|Jan 13, 2026

A multicentre phase 2 trial demonstrates that the combination of venetoclax and azacitidine achieves a 76% overall response rate in relapsed or refractory T-ALL, offering a manageable and effective alternative for a patient population with

Infectious Diseasesantifungal resistanceOlorofim

Olorofim Offers a New Salvage Option for Drug‑Resistant Invasive Fungal Disease — Phase 2b Results

By MedXY|Nov 24, 2025

Phase 2b data show olorofim has activity and acceptable tolerability in patients with invasive fungal disease and limited options, including azole‑resistant Aspergillus and intrinsically resistant moulds, supporting further controlled studi